



**PRESS RELEASE**

## **AMOEBa TO START R&D TESTS IN THE USA**

**Lyon (France), February 14th, 2017 - AMOEBa (FR0011051598 - AMEBa)**, producer of a biological biocide capable of eliminating bacterial risk in water, announced today its intention to start research field trials in the USA to be performed on industrial cooling towers.

According to the self-assessment of the Company in accordance with article 40 CFR Part 172 of the Federal Code, the R&D field tests will benefit from an exemption from an Experimental Use Permit at Federal level. As a result, AMOEBa will perform the tests on cooling towers with the following characteristics:

- With a blowdown volume, up to 9000 US gallons (34 m<sup>3</sup>)/ day
- And a direct cooling tower water discharge into a waste water treatment plant

Exemption criteria defined in 40 CFR Part 172 do not set any limitation on the number of possible sites which might be subject to the R&D tests in the USA. According to AMOEBa's published Reference Document\*, the potential market size of the USA is estimated at 5268m<sup>3</sup> of BIOMEBA product per annum. The volume required to treat cooling towers matching the exemption criteria would represent about 20% of the total volume per annum (i.e. 1000m<sup>3</sup>).

The R&D field tests in the USA will be fulfilled through the operational pilot unit located in Montreal (Canada), with a production capacity up to 30m<sup>3</sup> of biological biocide per annum over the next two years.

AMOEBa is confirming its intention to charge for services within the R&D framework for cooling towers in the USA, as soon as the tests start.

*\*page 62 of the Reference Document 2015 registered on April 27 2016 by the French Monetary Fund Authority under the number R-16-029*



*“The start of the R&D tests in the United States represents a significant milestone for AMOEBA to enter the commercial market. It allows us to carry out tests on highly representative panels of industries through different States and also gives us some valuable data to support our dossier submission and review with the EPA. The tests will raise considerable awareness for our product. Finally, it will enable our distribution network to gain the required know-how on the application and daily management of the BIOMEBA product.” stated **Fabrice PLASSON, President of AMOEBA’s Board of Directors.***



#### **About AMOEBA:**

AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector and complies with the new regulations in terms of chemical emissions into the environment. In a worldwide market for chemical biocides estimated to be worth EUR 21 bn<sup>(1)</sup>, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT), estimated to be worth EUR 1.7 bn<sup>(2)</sup>. AMOEBA is continuing with the regulatory procedures necessary to obtain provisional MA for all European countries for the “Air Cooled Towers” application. Based in Lyon-Chassieu (France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. For more information: [www.amoeba-biocide.com](http://www.amoeba-biocide.com).

(1): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

#### **Contacts:**

Amoéba  
Nathalie COMBROUSSE  
Marketing Communication Manager  
Tel. : +33 (0)4 81 09 18 15  
[nathalie.combrousse@amoeba-biocide.com](mailto:nathalie.combrousse@amoeba-biocide.com)

Actifin  
Ghislaine GASPARETTO  
Financial Communication  
Tel. : +33 (0)1 56 88 11 11  
[ggasparetto@actifin.fr](mailto:ggasparetto@actifin.fr)